NCT06175767: An ongoing trial by Mthera Pharma Co., Ltd.
This trial is ongoing. It must report results 7 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06175767 |
|---|---|
| Title | A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 14, 2025 |
| Completion date | July 31, 2025 |
| Required reporting date | July 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |